Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

doi:10.1111/1759-7714.14743

. 2023 Jan;14(1):91-104.

doi: 10.1111/1759-7714.14743. Epub 2022 Nov 28.

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Shirong Zhang¹, Wenxian Wang², Chunwei Xu^{3

4}, Yongchang Zhang⁵, Xiuyu Cai⁶, Qian Wang⁷, Zhengbo Song², Ziming Li⁸, Jinpu Yu⁹, Wenzhao Zhong¹⁰, Zhijie Wang¹¹, Jingjing Liu¹², Anwen Liu¹³, Wen Li¹⁴, Ping Zhan⁴, Hongbing Liu⁴, Tangfeng Lv⁴, Liyun Miao¹⁵, Lingfeng Min¹⁶, Gen Lin¹⁷, Long Huang¹³, Jingping Yuan¹⁸, Zhansheng Jiang¹⁹, Xingxiang Pu²⁰, Chuangzhou Rao²¹, Dongqing Lv²², Zongyang Yu²³, Xiaoyan Li²⁴, Chuanhao Tang²⁵, Chengzhi Zhou²⁶, Junping Zhang²⁷, Hui Guo²⁸, Qian Chu²⁹, Rui Meng³⁰, Xuewen Liu³¹, Jingxun Wu³², Jin Zhou³³, Zhengfei Zhu³⁴, Weiwei Pan³⁵, Xiaowei Dong³⁶, Fei Pang³⁶, Kai Wang³⁶, Chao Yao³⁶, Guomin Lin³⁶, Site Li³⁷, Zhi Yang³⁷, Jiancheng Luo³⁸, Hongtao Jia³⁸, Xiuqing Nie³⁹, Liping Wang⁴⁰, Youcai Zhu⁴¹, Xiao Hu⁴², Yanru Xie⁴³, Xinqing Lin²⁶, Jing Cai¹³, Yang Xia¹⁴, Huijing Feng²⁷, Lin Wang⁴⁴, Yingying Du⁴⁵, Wang Yao⁴⁶, Xuefei Shi⁴⁷, Xiaomin Niu⁸, Dongmei Yuan⁴, Yanwen Yao⁴, Jing Kang¹⁰, Jiatao Zhang¹⁰, Chao Zhang¹⁰, Wenbin Gao⁴⁸, Jianhui Huang⁴³, Yinbin Zhang⁴⁹, Pingli Sun⁵⁰, Hong Wang⁵¹, Mingxiang Ye⁴, Dong Wang⁴, Zhaofeng Wang⁴, Bing Wan⁵², Donglai Lv⁵³, Genhua Yu⁵⁴, Lin Shi⁵⁵, Yuanli Xia⁴¹, Feng Gao⁵⁶, Xiaochen Zhang⁵⁷, Tao Xu⁵⁸, Wei Zhou³, Haixia Wang³, Zhefeng Liu⁵¹, Nong Yang⁵, Lin Wu²⁰, Qiming Wang⁵⁹, Guansong Wang⁶⁰, Zhuan Hong⁶¹, Jiandong Wang⁶², Meiyu Fang², Yong Fang⁶³, Yiping Zhang², Yong Song⁴, Shenglin Ma⁶⁴, Wenfeng Fang⁶⁵, Yuanzhi Lu⁶⁶

Affiliations

¹ Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
² Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
³ Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.
⁴ Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
⁵ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
⁶ Department of VIP Inpatient, Sun Yet-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
⁷ Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
⁸ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
⁹ Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
¹⁰ Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China.
¹¹ State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹² Department of Thoracic Cancer, Jilin Cancer Hospital, Changchun, China.
¹³ Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
¹⁴ Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
¹⁵ Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
¹⁶ Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou, China.
¹⁷ Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China.
¹⁸ Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China.
¹⁹ Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
²⁰ Department of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
²¹ Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
²² Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, China.
²³ Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou, China.
²⁴ Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
²⁵ Department of Medical Oncology, Peking University International Hospital, Beijing, China.
²⁶ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease; Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University (The First Affiliated Hospital of Guangzhou Medical University), Guangzhou, China.
²⁷ Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China.
²⁸ Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
²⁹ Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³⁰ Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³¹ Department of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China.
³² Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen, China.
³³ Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology, Chengdu, China.
³⁴ Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
³⁵ Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing, China.
³⁶ Department of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China.
³⁷ Department of IVD Medical Marketing, 3D Medicines, Shanghai, China.
³⁸ Department of Medical, Aiyi Technology, Beijing, China.
³⁹ Department of Clinical Trial, Novocodex Biopharmaceutic, Shaoxing, China.
⁴⁰ Department of Oncology, Baotou Cancer Hospital, Baotou, China.
⁴¹ Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, China.
⁴² Zhejiang Key Laboratory of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
⁴³ Department of Oncology, Lishui Municipal Central Hospital, Lishui, China.
⁴⁴ Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China.
⁴⁵ Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
⁴⁶ Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
⁴⁷ Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, China.
⁴⁸ Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
⁴⁹ Department of Oncology, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China.
⁵⁰ Department of Pathology, The Second Hospital of Jilin University, Changchun, China.
⁵¹ Senior Department of Oncology, The 5th Medical Center of PLA General Hospital, Beijing, China.
⁵² Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
⁵³ Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, China.
⁵⁴ Department of Radiation Oncology, Zhebei Mingzhou Hospital, Huzhou, China.
⁵⁵ Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
⁵⁶ Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
⁵⁷ Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
⁵⁸ Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
⁵⁹ Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
⁶⁰ Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
⁶¹ Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
⁶² Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
⁶³ Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
⁶⁴ Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
⁶⁵ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
⁶⁶ Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

PMID: 36444143
PMCID: PMC9807451
DOI: 10.1111/1759-7714.14743

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Shirong Zhang et al. Thorac Cancer. 2023 Jan.

. 2023 Jan;14(1):91-104.

doi: 10.1111/1759-7714.14743. Epub 2022 Nov 28.

Authors

Affiliations

¹ Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
² Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
³ Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.
⁴ Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
⁵ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
⁶ Department of VIP Inpatient, Sun Yet-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
⁷ Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
⁸ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
⁹ Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
¹⁰ Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China.
¹¹ State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹² Department of Thoracic Cancer, Jilin Cancer Hospital, Changchun, China.
¹³ Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
¹⁴ Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
¹⁵ Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
¹⁶ Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou, China.
¹⁷ Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China.
¹⁸ Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China.
¹⁹ Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
²⁰ Department of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
²¹ Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
²² Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, China.
²³ Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou, China.
²⁴ Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
²⁵ Department of Medical Oncology, Peking University International Hospital, Beijing, China.
²⁶ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease; Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University (The First Affiliated Hospital of Guangzhou Medical University), Guangzhou, China.
²⁷ Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China.
²⁸ Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
²⁹ Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³⁰ Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³¹ Department of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China.
³² Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen, China.
³³ Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology, Chengdu, China.
³⁴ Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
³⁵ Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing, China.
³⁶ Department of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China.
³⁷ Department of IVD Medical Marketing, 3D Medicines, Shanghai, China.
³⁸ Department of Medical, Aiyi Technology, Beijing, China.
³⁹ Department of Clinical Trial, Novocodex Biopharmaceutic, Shaoxing, China.
⁴⁰ Department of Oncology, Baotou Cancer Hospital, Baotou, China.
⁴¹ Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, China.
⁴² Zhejiang Key Laboratory of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
⁴³ Department of Oncology, Lishui Municipal Central Hospital, Lishui, China.
⁴⁴ Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China.
⁴⁵ Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
⁴⁶ Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
⁴⁷ Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, China.
⁴⁸ Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
⁴⁹ Department of Oncology, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China.
⁵⁰ Department of Pathology, The Second Hospital of Jilin University, Changchun, China.
⁵¹ Senior Department of Oncology, The 5th Medical Center of PLA General Hospital, Beijing, China.
⁵² Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
⁵³ Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, China.
⁵⁴ Department of Radiation Oncology, Zhebei Mingzhou Hospital, Huzhou, China.
⁵⁵ Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
⁵⁶ Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
⁵⁷ Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
⁵⁸ Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
⁵⁹ Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
⁶⁰ Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
⁶¹ Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
⁶² Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
⁶³ Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
⁶⁴ Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
⁶⁵ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
⁶⁶ Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

PMID: 36444143
PMCID: PMC9807451
DOI: 10.1111/1759-7714.14743

Abstract

Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T-DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2-mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2-targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2-altered NSCLC, focusing on the diagnosis and treatment strategies.

Keywords: antibody-drug conjugate; non-small cell lung cancer; precision medicine; targeted therapy; tyrosine receptor kinase.

PubMed Disclaimer

Figures

**FIGURE 1**
Frequency and location of *HER2* hotspots in non–small cell lung cancer.

**FIGURE 2**
Judgment criteria of *HER2* dual probe in situ hybridization testing.

**FIGURE 3**
Judgment criteria of HER2 overexpression testing. HER2, human epidermal growth factor receptor 2.

**FIGURE 4**
Strategy of HER2 testing in NSCLC. HER2, human epidermal growth factor receptor 2; NSCLC, non–small cell lung cancer.

See this image and copyright information in PMC

Cited by

Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects.
Chen P, Chu Y, Liu R. Chen P, et al. Immunother Adv. 2024 Apr 25;4(1):ltae003. doi: 10.1093/immadv/ltae003. eCollection 2024. Immunother Adv. 2024. PMID: 38736973 Free PMC article. Review.
Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study.
Zhang M, Wang L, Wang Q, Yang J, Peng W, Li X, Shi M, Lu K. Zhang M, et al. Front Oncol. 2024 Nov 6;14:1441025. doi: 10.3389/fonc.2024.1441025. eCollection 2024. Front Oncol. 2024. PMID: 39568568 Free PMC article.
A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC.
Shao J, Gu Y, Guo R, Xu J. Shao J, et al. Drug Des Devel Ther. 2024 Jun 26;18:2571-2591. doi: 10.2147/DDDT.S465238. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38947223 Free PMC article.
Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review.
Pan X, Zhou X. Pan X, et al. Front Oncol. 2024 Aug 9;14:1397238. doi: 10.3389/fonc.2024.1397238. eCollection 2024. Front Oncol. 2024. PMID: 39184039 Free PMC article.
The diagnostic value of ⁶⁸Ga-NOTA-MAL-Cys-MZHER_2:342 PET/CT imaging for HER2-positive lung adenocarcinoma.
Li S, Wang K, Zhu X, Pan D, Wang L, Guo X, Gao X, Luo Q, Wang X. Li S, et al. Front Med (Lausanne). 2024 Aug 13;11:1447500. doi: 10.3389/fmed.2024.1447500. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39193019 Free PMC article.

References

1. Yang G, Yang Y, Liu R, et al. First‐line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2‐altered NSCLC: a retrospective real‐world POLISH study. Ther Adv Med Oncol. 2022;14:17588359221082339. - PMC - PubMed
1. Cornelissen R, Sun S, Wollner M, Garassino MCC, Prelaj A, Haura EB, et al. LBA46‐efficacy and safety of poziotinib in treatment‐naïve NSCLC harboring HER2 exon 20 mutations: a multinational phase II study (ZENITH20‐4) Ann. Oncologia. 2021;32:S1283–346.
1. Zhou C, Li X, Wang Q. Pyrotinib in HER2‐mutant advanced lung adenocarcinoma after platinum‐based chemotherapy: a multicenter, open‐label, single‐arm, phase II study. J Clin Oncol. 2020;38(24):2753–61. - PubMed
1. Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado‐Trastuzumab Emtansine for patients with HER2‐mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532–7. - PMC - PubMed
1. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab Deruxtecan in HER2‐mutant non‐Small‐cell lung cancer. N Engl J Med. 2022;386:241–51. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Yang G, Yang Y, Liu R, et al. First‐line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2‐altered NSCLC: a retrospective real‐world POLISH study. Ther Adv Med Oncol. 2022;14:17588359221082339. - PMC - PubMed

[2] Yang G, Yang Y, Liu R, et al. First‐line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2‐altered NSCLC: a retrospective real‐world POLISH study. Ther Adv Med Oncol. 2022;14:17588359221082339. - PMC - PubMed

[3] Cornelissen R, Sun S, Wollner M, Garassino MCC, Prelaj A, Haura EB, et al. LBA46‐efficacy and safety of poziotinib in treatment‐naïve NSCLC harboring HER2 exon 20 mutations: a multinational phase II study (ZENITH20‐4) Ann. Oncologia. 2021;32:S1283–346.

[4] Cornelissen R, Sun S, Wollner M, Garassino MCC, Prelaj A, Haura EB, et al. LBA46‐efficacy and safety of poziotinib in treatment‐naïve NSCLC harboring HER2 exon 20 mutations: a multinational phase II study (ZENITH20‐4) Ann. Oncologia. 2021;32:S1283–346.

[5] Zhou C, Li X, Wang Q. Pyrotinib in HER2‐mutant advanced lung adenocarcinoma after platinum‐based chemotherapy: a multicenter, open‐label, single‐arm, phase II study. J Clin Oncol. 2020;38(24):2753–61. - PubMed

[6] Zhou C, Li X, Wang Q. Pyrotinib in HER2‐mutant advanced lung adenocarcinoma after platinum‐based chemotherapy: a multicenter, open‐label, single‐arm, phase II study. J Clin Oncol. 2020;38(24):2753–61. - PubMed

[7] Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado‐Trastuzumab Emtansine for patients with HER2‐mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532–7. - PMC - PubMed

[8] Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado‐Trastuzumab Emtansine for patients with HER2‐mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532–7. - PMC - PubMed

[9] Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab Deruxtecan in HER2‐mutant non‐Small‐cell lung cancer. N Engl J Med. 2022;386:241–51. - PMC - PubMed

[10] Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab Deruxtecan in HER2‐mutant non‐Small‐cell lung cancer. N Engl J Med. 2022;386:241–51. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Affiliations

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous